Literature DB >> 22280200

Methods and issues associated with the use of quality-adjusted life-years.

Dennis A Revicki1, William R Lenderking.   

Abstract

In this article, we will focus on how preferences and utilities are measured, including the strengths and limitations of various approaches, discuss their use in estimating quality-adjusted life-years (QALYs) and make some recommendations for further research. Preferences are either measured using direct (visual analog scale, time trade-off or standard gamble) or indirect methods. The most commonly used generic indirect measures include the Quality of Well-Being scale, EuroQol-5 Dimension, Health Utilities Index and Short Form-6 Dimension. Disease-specific preference measures are increasingly being developed and applied in studies as more sensitive measures of health status. Preference-based measures and QALY measurement need to be enhanced, and additional research is needed to improve scientific methods for estimating preferences for health assessment. Given the increased focus on comparative effectiveness research, QALYs have the potential for helping researchers, clinicians, health policy-makers and patients to understand the relative effectiveness of alternative interventions for treating medical conditions.

Entities:  

Mesh:

Year:  2012        PMID: 22280200     DOI: 10.1586/erp.11.100

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  8 in total

1.  Universal late pregnancy ultrasound screening to predict adverse outcomes in nulliparous women: a systematic review and cost-effectiveness analysis.

Authors:  Gordon Cs Smith; Alexandros A Moraitis; David Wastlund; Jim G Thornton; Aris Papageorghiou; Julia Sanders; Alexander Ep Heazell; Stephen C Robson; Ulla Sovio; Peter Brocklehurst; Edward Cf Wilson
Journal:  Health Technol Assess       Date:  2021-02       Impact factor: 4.014

Review 2.  Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.

Authors:  Scott D Grosse; Shraddha S Chaugule; Joel W Hay
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-01-14       Impact factor: 2.217

Review 3.  Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials.

Authors:  Cindy J Nowinski; Deborah M Miller; David Cella
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

4.  Comparing and transforming PROMIS utility values to the EQ-5D.

Authors:  John D Hartman; Benjamin M Craig
Journal:  Qual Life Res       Date:  2017-12-20       Impact factor: 4.147

5.  Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B.

Authors:  Y X Jia; F Q Cui; L Li; D L Zhang; G M Zhang; F Z Wang; X H Gong; H Zheng; Z H Wu; N Miao; X J Sun; L Zhang; J J Lv; F Yang
Journal:  Qual Life Res       Date:  2014-03-14       Impact factor: 4.147

6.  The Diagnosis of Urinary Tract Infection in Young Children (DUTY) Study Clinical Rule: Economic Evaluation.

Authors:  William Hollingworth; John Busby; Christopher C Butler; Kathryn O'Brien; Jonathan A C Sterne; Kerenza Hood; Paul Little; Michael Lawton; Kate Birnie; Emma Thomas-Jones; Kim Harman; Alastair D Hay
Journal:  Value Health       Date:  2017-02-22       Impact factor: 5.725

7.  Evaluation of health status in patients with hepatitis c treated with and without interferon.

Authors:  R Ragusa; G Bertino; A Bruno; E Frazzetto; F Cicciu; G Giorgianni; L Lupo
Journal:  Health Qual Life Outcomes       Date:  2018-01-17       Impact factor: 3.186

8.  Implications of response shift for micro-, meso-, and macro-level healthcare decision-making using results of patient-reported outcome measures.

Authors:  Richard Sawatzky; Jae-Yung Kwon; Ruth Barclay; Cynthia Chauhan; Lori Frank; Wilbert B van den Hout; Lene Kongsgaard Nielsen; Sandra Nolte; Mirjam A G Sprangers
Journal:  Qual Life Res       Date:  2021-03-02       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.